Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.
Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.
